Search
Pozelimab
go.drugbank.com/drugs/DB15218ApprovedInvestigationalautoimmune hemolysis that are often observed in CHAPLE disease. … CD55-deficient protein-losing enteropathy (PLE), or CHAPLE disease, is an ultra-rare hereditary disease, with fewer than 100 patients diagnosed worldwide or fewer than 10 patients in the US.
MDX-214
go.drugbank.com/drugs/DB06110ExperimentalIt is developed for the treatment of EGF-R overexpressing cancers. … MDX-214 consists of recombinant human epidermal growth factor (EGF) genetically linked to a fully human antibody fragment that is designed to activate cytotoxic killing of cancer cells by immune effector
Potassium permanganate
go.drugbank.com/drugs/DB13831InvestigationalCategories: Compounds used in a research, industrial, or household settingDipicolinic acid
go.drugbank.com/drugs/DB04267ExperimentalCategories: Compounds used in a research, industrial, or household settingBizelesin
go.drugbank.com/drugs/DB12352InvestigationalBizelesin has been used in trials studying the treatment of Unspecified Adult Solid Tumor, Protocol Specific.
Categories: Compounds used in a research, industrial, or household settingGacyclidine
go.drugbank.com/drugs/DB13096InvestigationalGacyclidine has been used in trials studying the treatment of Tinnitus.
Categories: Compounds used in a research, industrial, or household settingElacridar
go.drugbank.com/drugs/DB04881InvestigationalIn many cases, the appearance of multidrug resistance in cancer is due to a change in expression of protein inhibitors. As of August 2007 elacridar was not listed on GSK's product pipeline. … Elacridar (GW120918) is an oral bioenhancer that targets multiple drug resistance in tumors.
Varespladib methyl
go.drugbank.com/drugs/DB05737InvestigationalStudies showed that Varespladib methyl treatment resulted in significant positive changes on lipoproteins and inflammation.
TB-402
go.drugbank.com/drugs/DB06050InvestigationalTB-402 is a human antibody binding to Factor VIII, which plays a crucial role in the coagulation of the blood. … It is expected to be developed as a potential treatment to prevent blood clot formation in connection with certain types of heart arrhythmia, such as atrial fibrillation.
Resiquimod
go.drugbank.com/drugs/DB06530InvestigationalA substance being studied in the treatment of some types of skin cancer. When put on the skin, resiquimod causes some immune cells to make certain chemicals that may help them kill tumor cells. … It is also being studied to find out if adding it to a tumor vaccine improves the antitumor immune response. It is a type of imidazoquinoline and a type of immunomodulator.